Congress Coverage: ASH 2021 – Focus on Leukemia

Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia.

December 15, 2021

Faculty Co-Chair

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Faculty Co-Chair

Nicola Gökbuget, MD

Goethe University Hospital, Frankfurt, Germany

Faculty Members

Naval Daver, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, US

Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, US

Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, NY, US

Amir Fathi, MD
Massachusetts General Hospital, Boston, MA, US

Josep-Maria Ribera, MD, PhD
Hospital Universitari Germans Trias i Pujol, Barcelona, Spain

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci
Queen Elizabeth Hospital, Birmingham, UK

Valeria Santini, MD
University of Florence, Firenze, Italy

Sample Report

Start discovering the insights

View Report

REPORT SNAPSHOT

The report was based on the following topics

  • New Developments in MDS
  • Advances in AML: Newly Diagnosed
  • Advances in AML: Relapsed/Refractory
  • Advances in ALL: Newly Diagnosed
  • Advances in ALL: Relapsed/Refractory

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.